Table 2 Efficacy outcome: reduction in cytokines plasma levels within 48 h post-randomization
Control (n = 10*) | Hemoadsorption (n = 8*) | Total (n = 18) | p value | |
|---|---|---|---|---|
IL-6 | ||||
Absolute reduction, pg/mL | 4.18 (− 13, 639) | 143 (42, 19,555) | 43 (− 7, 792) | 0.38 |
Relative reduction, % | 5 (− 47, 7) | 75 (60, 94) | 60 (− 13, 86) | 0.06 |
IL-8 | ||||
Absolute reduction, pg/mL | 59 (10, 187) | 181 (21, 345) | 128 (16, 266) | 0.37 |
Relative reduction, % | 72 (13, 90) | 90 (68, 98) | 83 (33, 93) | 0.06 |
IL-10 | ||||
Absolute reduction, pg/mL | 15 (4, 140) | 82 (0.15, 617) | 20 (2, 366) | 0.59 |
Relative reduction, % | 62 (41, 76) | 91 (35, 99) | 75 (41, 92) | 0.20 |
TNF-α | ||||
Absolute reduction, pg/mL | 0.15 (− 0.46, 1.71) | 1.35 (− 0.25, 1.56) | 0.84 (− 0.46, 1.56) | 0.72 |
Relative reduction, % | 60 (5, 100) | 100 (96, 100) | 98 (25, 100) | 0.29 |
IL-5 | ||||
Absolute reduction, pg/mL | 0.12 (− 0.41, 0.83) | 1.35 (0.09, 3.00) | 0.78 (− 0.41, 1.51) | 0.25 |
Relative reduction, % | 20 (2, 100) | 100 (89, 100) | 94 (4, 100) | 0.10 |
IL-2 | ||||
Absolute reduction, pg/mL | 0.00 (0.00, 3.58) | 3.47 (− 2.63, 6.59) | 0.00 (0.00, 5.26) | 0.39 |
Relative reduction, % | 77 (35, 90) | 82 (63, 100) | 77 (63, 100) | 0.67 |
IL-4 | ||||
Absolute reduction, pg/mL | 0.00 (− 1.60, 1.39) | 12.35 (1.20, 37.97) | 0.69 (− 1.39, 13.57) | 0.07 |
Relative reduction, % | 38 (− 14, 93) | 84 (72, 97) | 75 (16, 97) | 0.47 |
GM-CSF | ||||
Absolute reduction, pg/mL | 0.04 (− 0.35, 0.35) | 0.65 (0.02, 3.86) | 0.13 (− 0.21, 1.20) | 0.16 |
Relative reduction, % | 2 (− 14, 16) | 27 (2, 49) | 8 (− 14, 31) | 0.16 |